Equities research analysts expect Replimune Group Inc (NASDAQ:REPL) to post ($0.34) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Replimune Group’s earnings, with the highest EPS estimate coming in at ($0.26) and the lowest estimate coming in at ($0.39). Replimune Group reported earnings of ($0.26) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 30.8%. The firm is scheduled to report its next quarterly earnings report on Wednesday, November 13th.

According to Zacks, analysts expect that Replimune Group will report full year earnings of ($1.52) per share for the current financial year, with EPS estimates ranging from ($2.03) to ($1.19). For the next financial year, analysts anticipate that the firm will report earnings of ($1.49) per share, with EPS estimates ranging from ($1.90) to ($1.25). Zacks’ EPS averages are an average based on a survey of research analysts that cover Replimune Group.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.02.

Several brokerages have commented on REPL. Chardan Capital reissued a “buy” rating and set a $28.00 price objective on shares of Replimune Group in a research report on Thursday, August 15th. Zacks Investment Research downgraded shares of Replimune Group from a “buy” rating to a “hold” rating in a research report on Tuesday, August 20th. ValuEngine upgraded shares of Replimune Group from a “hold” rating to a “buy” rating in a research note on Monday, August 12th. JPMorgan Chase & Co. raised shares of Replimune Group from a “neutral” rating to an “overweight” rating and lowered their price target for the company from $27.00 to $26.00 in a research report on Friday, July 12th. Finally, Roth Capital started coverage on shares of Replimune Group in a research report on Wednesday, September 4th. They set a “buy” rating and a $20.00 price target for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Replimune Group currently has an average rating of “Buy” and an average target price of $23.33.

Several institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its position in Replimune Group by 21.2% during the 4th quarter. Bank of New York Mellon Corp now owns 24,049 shares of the company’s stock valued at $240,000 after buying an additional 4,209 shares in the last quarter. Geode Capital Management LLC raised its stake in Replimune Group by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 52,687 shares of the company’s stock valued at $526,000 after buying an additional 6,878 shares during the last quarter. BNP Paribas Arbitrage SA bought a new stake in Replimune Group in the first quarter worth $38,000. Rhumbline Advisers bought a new stake in Replimune Group in the first quarter worth $174,000. Finally, Victory Capital Management Inc. boosted its holdings in Replimune Group by 40.4% in the first quarter. Victory Capital Management Inc. now owns 177,090 shares of the company’s stock worth $2,695,000 after acquiring an additional 50,950 shares in the last quarter. Institutional investors own 60.74% of the company’s stock.

REPL traded up $0.73 during trading on Wednesday, reaching $11.78. The stock had a trading volume of 24,473 shares, compared to its average volume of 54,314. The stock’s 50 day moving average is $11.23 and its two-hundred day moving average is $13.32. The company has a market capitalization of $346.74 million, a price-to-earnings ratio of -8.86 and a beta of 3.12. Replimune Group has a one year low of $8.88 and a one year high of $20.02.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Featured Article: What defines an oversold asset?

Get a free copy of the Zacks research report on Replimune Group (REPL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.